Related Experiment Videos
Hepatitis C: reality of a renal unit
1Servizio di Nefrologia e Dialisi, Ospedale Predabissi, Melegnano, Italy.
Nephron
|January 1, 1992
Summary
Hepatitis C virus (HCV) is common in kidney dialysis patients, with 29% testing positive for anti-HCV antibodies. This highlights the importance of parenteral transmission and potential liver disease risk in this population.
Area of Science:
- Hepatology
- Nephrology
- Virology
Background:
- Hepatitis C virus (HCV) is a primary cause of non-A, non-B hepatitis.
- Renal units are a critical focus for studying HCV prevalence due to patient vulnerabilities.
Purpose of the Study:
- To determine the prevalence of Hepatitis C virus (HCV) infection within a specific renal unit.
- To identify risk factors and associations with HCV seropositivity in hemodialysis patients.
Main Methods:
- Serological testing for antibodies against HCV (anti-HCV) was performed on patients undergoing hemodialysis.
- Patient data, including duration of hemodialysis and history of elevated transaminases, were analyzed for correlations with anti-HCV status.
Main Results:
- Twenty-nine percent (12/41) of patients tested positive for anti-HCV antibodies.
- Seropositive patients had a longer duration of hemodialysis compared to seronegative patients.
- Significant associations were found between anti-HCV positivity and blood transfusions, elevated transaminase episodes, and transaminase fluctuations.
Conclusions:
- The study confirms a high prevalence of anti-HCV in hemodialysis patients.
- Parenteral transmission routes are critically important in this patient group.
- Anti-HCV-positive patients have a high probability of developing liver disease.